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Abstract 
Purpose: Socioeconomic status (SES) is a known predictor of survival for several cancers 
and it has been suggested that SES differences affecting tumour stage at diagnosis may be the 
most important explanatory factor for this. However, only a limited number of studies have 
investigated SES differences in tumour stage at diagnosis of ovarian cancer. In a pooled 
analysis, we investigated whether SES as represented by level of education is predictive for 
advanced tumour stage at diagnosis of ovarian cancer, overall and by histotype. The effect of 
cigarette smoking and body mass index (BMI) on the association was also evaluated. 
Methods: From 18 case-control studies, we obtained information on 10,601 women 
diagnosed with epithelial ovarian cancer. Study specific odds ratios (ORs) with corresponding 
95% confidence intervals (CI) were obtained from logistic regression models and combined 
into a pooled odds ratio (pOR) using a random effects model.  
Results: Overall, women who completed ≤high school had an increased risk of advanced 
tumour stage at diagnosis compared with women who completed >high school (pOR 1.15; 
95% CI 1.03-1.28). The risk estimates for the different histotypes of ovarian cancer resembled 
that observed for ovarian cancers combined but did not reach statistical significance. Our 
results were unchanged when we included BMI and cigarette smoking. 
Conclusion: Lower level of education was associated with an increased risk of advanced 
tumour stage at diagnosis of ovarian cancer. The observed socioeconomic difference in stage 
at diagnosis of ovarian cancer calls for further studies on how to reduce this diagnostic delay.  
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1. Introduction 
Ovarian cancer is the 5th most common malignancy among women in developed countries [1]. 
Furthermore, it is a highly fatal disease with the worst prognosis among the gynaecological 
cancers because it is often diagnosed at an advanced tumour stage [2]. As tumour stage at 
diagnosis is among the most important prognostic factors in ovarian cancer, detection at an 
early stage is essential. However, currently there are no efficient screening tools for ovarian 
cancer and as most women only experience vague symptoms, the disease is often detected at 
an advanced stage when survival is poor. Therefore, knowledge on predictors for advanced 
stage at diagnosis of ovarian cancer is crucial to reduce the mortality for this disease.  
 
Socioeconomic status (SES) is a predictor of incidence and survival of a number of diseases 
and there is evolving evidence for socioeconomic differences in cancer survival for many 
cancer types [3;4]. However, in contrast to breast cancer, relatively few studies have 
addressed the association between SES and ovarian cancer survival and the results have been 
inconsistent. Five studies [5-9] found worse survival among women with low SES whereas 
two studies [10;11] found no association. The reasons for socioeconomic differences in cancer 
survival in general and ovarian cancer survival in particular are not well-understood [4]. 
Possible underlying causes can be separated into three groups: tumour characteristics (tumour 
stage at diagnosis and biological characteristics), health care factors (e.g., types of treatment 
received, medical expertise and utilization of screening), and patient characteristics (e.g., 
lifestyle factors and comorbidities) [4]. According to Woods et al. [4], SES differences in 
tumour stage at diagnosis is likely the most important explanation for differences in cancer 
survival for a number of cancer types; including  breast- [12], endometrial- [13] and cervical 
cancer [14]. SES differences in tumour stage at diagnosis may be attributable to several 
reasons, including access to and acceptance of cancer screening technologies, awareness of 
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cancer symptoms, health-seeking behaviour, access to health care, comorbidities, and lifestyle 
factors.  
 
However, only a limited number of studies have investigated SES differences in tumour stage 
at diagnosis of ovarian cancer, and whereas the majority found no convincing evidence that 
tumour stage at diagnosis differed according to SES [15-18], one recent study showed that a 
lower level of education was associated with advanced tumour stage at diagnosis of ovarian 
cancer [8]. Many of the previous studies were limited by small sample sizes and lack of 
individual level SES data, and none of the studies investigated whether the association 
between SES and tumour stage at diagnosis differed by histotype.  
 
Using data from 18 case-control studies included in the international Ovarian Cancer 
Association Consortium (OCAC), we performed a pooled analysis in order to evaluate the 
association between SES (represented by highest obtained level of education) and tumour 
stage at diagnosis, overall and by histotype. Furthermore, we aimed to investigate to what 
degree the association between SES and tumour stage at diagnosis was confounded by pre-
diagnosis cigarette smoking or by body mass index (BMI). 
 
2. Materials and Methods  
The Ovarian Cancer Association Consortium (OCAC) described in details elsewhere [19] is 
an international collaboration of case-control studies founded in 2005 with the original aim to 
identify genetic polymorphisms associated with ovarian carcinogenesis. More recently, 
consortial activities have included the identification of risk factors and prognostic factors for 
ovarian cancer. In the present study, we obtained data from 18 studies that provided 
information about level of education and other required variables for the study [20-37] (Table 
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1). All data were checked for internal consistencies and clarifications were provided by the 
original investigators if needed. Among women diagnosed with ovarian cancer, we excluded 
from analyses those with missing data for level of education, those with non-epithelial ovarian 
tumours or epithelial tumours of low malignant potential (borderline ovarian tumours) and 
those who lacked information on age, race/ethnicity or tumour stage at diagnosis, leaving 
10,601 women for analysis. All individual studies included in OCAC had institutional review 
board or ethics committee approvals and all study participants provided informed consent.  
 
2.1. Assessment of level of education  
Information on highest attained level of education was obtained either from self-administered 
questionnaires (n = 8 studies) or from in-person interviews (n = 10 studies). For all included 
OCAC studies, information on highest level of education was harmonized and parameterized 
as a dichotomous variable (≤high school versus >high school).  
 
2.2. Statistical analysis  
Of the 18 studies included for analyses, 11 (AUS, GER, HOP, MAL, MAY, NCO, NEC, 
NTH, POL, SEA and UKO) used the FIGO staging system [38], while two studies (CON and 
NJO) used SEER staging manuals [39] to stage ovarian cancer. Five studies (DOV, HAW, 
STA, UCI and USC) had information on both FIGO and SEER tumour staging. In the 
common OCAC dataset, a harmonized summary tumour stage variable was created and 
reported in the following categories: localized tumour stage, regional tumour stage or distant 
tumour stage, using the following algorithm: localized = FIGO tumour stage IA, IB, I (not 
other specified (NOS)) or SEER tumour stage 1; regional = FIGO tumour stage IC, IIA, IIB, 
IIC, II (NOS) or SEER tumour stage 2, 3, 4, 5; distant = FIGO tumour stage IIIA, IIIB, IIIC, 
III (NOS), IV or SEER tumour stage 7. For studies with information on both FIGO and SEER 
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tumour staging, the harmonized summary tumour stage variable represents the more advanced 
of FIGO and SEER tumour stage. In all analyses, the harmonized OCAC tumour stage 
variable was parameterized as a dichotomous comparison of localized tumour stage or 
advanced tumour stage (regional or distant).  
 
To compare characteristics of the included women according to tumor stage at diagnosis  
(localized stage versus advanced stage), a Pearson's chi square statistical test was used when 
data were normally distributed (histology, level of education, smoking status and 
race/ethnicity) and a Wilcoxon rank sum statistical test was used when data were not normally 
distributed (age at diagnosis and BMI). We used a two-stage approach [40] to analyse the 
association between stage of ovarian cancer and level of education. First, study-specific odds 
ratios (ORs) were obtained by logistic regression models with adjustments for a priori 
selected potential confounding variables (described below). The study-specific estimates were 
then combined by random-effects inverse variance-weighted meta-analysis into a pooled odds 
ratio (pOR) with corresponding 95% confidence intervals (CIs) [41]. Statistical heterogeneity 
among studies was evaluated using the Cochran Q and I2 statistics. For all analyses, individual 
studies were included in the meta-analysis only if the following two requirements were met; i) 
five cases with complete data were available and ii) each level of the tumour stage variable 
had one or more subjects.  
 
Two statistical models were fitted to evaluate the association of tumour stage at diagnosis of 
ovarian cancer according to level of education. Model 1 included adjustments for age at 
diagnosis (continuous variable) and race/ethnicity (non-Hispanic White, Hispanic White, 
Black, Asian or other, including unknown races). In Model 2, we additionally adjusted for 
pre-diagnosis cigarette smoking (never, former or current smoker) and BMI (determined 
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either at one or five years prior to ovarian cancer diagnosis, depending on the study) as a 
continuous variable (per 5 kg/m2). Subgroup analyses were conducted for specific histotypes 
of ovarian cancers including serous, mucinous, endometrioid and clear cell tumours. Serous 
tumours were additionally categorized as low- (grade 1) or high- (grade 2+) grade tumours. 
Finally, we also performed additional sensitivity analyses to investigate whether the 
association between level of education and tumour stage at diagnosis of ovarian cancer overall 
differed according to study continent (US versus non-US studies), race/ethnicity (white (non-
Hispanic or Hispanic White) versus all other races/ethnicities (Black, Asian and other)) or 
study type (population-based versus hospital-/clinic-based studies). All analyses were 
conducted using the environment R, version 3.1.0. A 5% significance level was used for all 
analysis. 
 
3. Results 
Characteristics of the 18 studies that contributed data from 10,601 women with epithelial 
ovarian cancer are shown in Table 1. Eleven studies were conducted in the United States 
(US), six in Europe and one in Australia. In the studies, the number of women with ovarian 
cancer ranged from 183 to 1377. Women were 19-91 years of age at diagnosis between 1989 
and 2010. Fifteen studies were population-based and three were hospital/clinic-based. Almost 
four-fifths of the women (78.6%) had advanced tumour stage (regional or distant) at diagnosis 
of ovarian cancer. 
 
Table 2 presents characteristics of the women included in the analysis according to tumour 
stage at diagnosis of ovarian cancer. Among women diagnosed at advanced tumour stage, 
median age at diagnosis was significantly higher (58.0 years) compared with women 
diagnosed at localized tumour stage (median age = 53.0 years). Furthermore, women 
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diagnosed at advanced tumour stage of ovarian cancer were more often diagnosed with serous 
tumours, had completed ≤high school, had higher BMI, were less likely to be Asian and were 
more often a former smoker, compared with women diagnosed at a localized tumour stage (all 
p-values < 0.01).  
 
In Table 3 are presented the pooled odds ratios for advanced tumour stage at diagnosis of 
ovarian cancer overall and within histotypes according to level of education. The table shows 
pORs based on two analytic models: Model 1 includes adjustment for age and race/ethnicity 
and Model 2 includes additional adjustment for BMI and cigarette smoking status. Women 
who completed high school or less had an increased risk of advanced tumour stage at 
diagnosis of ovarian cancer (pOR 1.15; 95% CI 1.03-1.28) (Table 3, Model 1; Figure 1). The 
risk estimates for the various histotypes generally resembled that for ovarian cancer overall, 
though none of the risk estimates reached nominal statistical significance (Table 3, Model 1). 
Additional adjustments for BMI and cigarette smoking status made virtually no changes to the 
estimated associations between level of education and tumour stage at diagnosis of ovarian 
cancer (Table 3, Model 2). Heterogeneity was not evident for any of the analyses included in 
the present paper (All p-values > 0.4 and all I2 <5%).  
 
Lastly, we performed sensitivity analyses to investigate whether the association between level 
of education and tumour stage at diagnosis of ovarian cancer overall differed according to 
study continent, race/ethnicity or study type. However, the direction and the magnitude of the 
associations were not markedly different from the associations obtained in the main analyses 
(Table 3). Further, the risk estimates did not differ statistically significantly between the US 
studies (pOR 1.11; 95% CI 0.97-1.28) and the non-US studies (pOR 1.22; 95% CI 1.01-1.47), 
between women of white race/ethnicity (pOR 1.15; 95% CI 1.02-1.29) and women of other 
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races/ethnicities (pOR 1.13; 95% CI 0.84-1.51), as well as between population-based studies 
(pOR 1.14; 95% CI 1.01-1.28) and hospital-/clinic-based studies (pOR 1.28; 95% CI 0.88-
1.73) (all p-values for pairwise comparisons >0.05).  
 
4. Discussion 
Tumour stage is the most important prognostic factor of survival in ovarian cancer. It is 
therefore important to identify factors that predict tumour stage at diagnosis. A potential 
candidate is socioeconomic status, which has been found to be associated with tumour stage at 
diagnosis for other gynaecological cancers [12-14]. The present large study evaluated the 
association between level of education and tumour stage at diagnosis of epithelial ovarian 
cancer. Our results showed that women who completed high school or less had a modest 
(15%) increased risk of advanced tumour stage at diagnosis of ovarian cancer compared with 
women who completed more than high school. Observed risk estimates for the histotypes 
resembled those for ovarian cancer overall.  
 
Only a few studies have investigated SES differences in tumour stage at diagnosis of ovarian 
cancer. Our results are partly in line with results from a recent Danish cohort study. Ibfelt et 
al. [8], with data of 2873 women diagnosed with ovarian cancer, observed that women with 
medium level of education (10-12 years) had a 25% increased risk of advanced tumour stage 
at diagnosis of ovarian cancer compared with women with high level of education (>12 
years). However, the authors found no association between risk of advanced tumour stage and 
short level of education (7-9 years). Other studies have found no convincing associations 
between various measures of SES and tumour stage at diagnosis of ovarian cancer [15-18]. 
For example, in the largest study to date using data from 16,228 American women with 
ovarian cancer, Morris et al. [18] found no association between a census-based measure of 
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SES and tumour stage at diagnosis. An explanation for the divergent results may be that only 
our study and the study by Ibfelt et al. [8] used individual level measures of SES, whereas all 
other studies of this question have used various area-based/aggregate measures of SES as 
surrogates for individual SES. Area-based and aggregate measures of SES are known to be 
less precise (i.e., have higher risk of misclassification) than individual measures of SES and 
likely to bias relative risk toward the null in epidemiological studies [42]. No previous studies 
have examined whether or not the association between SES and tumour stage at diagnosis of 
ovarian cancer differs by histotype. We observed that the estimated risks for the histotypes of 
ovarian cancer resembled that for ovarian cancer overall. However, the numbers of cases for 
some of the histotypes were relatively small and additional confirmation would be warranted. 
 
The observed association between educational level and tumour stage at diagnosis is likely to 
be explained by a complex interaction between several underlying factors, including patient 
access to regular health-care check-ups, patient awareness of cancer symptoms, adequate 
reaction to symptoms, access, barriers and quality of healthcare, time-period to referral to 
specialist care, lifestyle factors, and comorbidities. Cancer symptom awareness and 
interpretation of symptoms is poorer among those who are less educated and those with lower 
SES [43]. Though some ovarian cancers are asymptomatic, most women experience vague or 
non-specific symptoms, which are similar to those of other common illnesses [44]. Therefore, 
it is plausible that more highly educated women could be more aware of and able to recognize 
potential symptoms compared with less educated women and may therefore be more likely to 
seek medical care earlier, which would eventually lead to a diagnosis of ovarian cancer in an 
earlier tumour stage. However, compared with cancers that are generally screenable or present 
with clear clinical signs, the potential for socioeconomic status to have an influence on 
awareness of symptoms and health-care seeking in ovarian cancer are likely to be rather 
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limited. Alternatively, women that are more educated might respond more promptly to their 
apparent signs or symptoms whereas less educated women may be more likely to ignore, 
discount or deny them until mounting discomfort becomes substantial in advanced tumour 
stage disease. 
 
Regular visits to a primary care physician and the latency from date of visit at the general 
practitioner until referral to a gynaecologist are both factors that are potentially predictive for 
tumour stage at diagnosis of ovarian cancer. As low SES is associated with less frequent use 
of primary care [45] and likely increased time to referral to a specialist, these factors may 
combine to explain the observed association between educational level and tumour stage at 
diagnosis. In the present study, 11 of 18 individual studies were conducted in the USA, 
representing 65% of the women in our study population. In contrast to Europe and Australia, 
access to health care in the USA is not uniform and a larger proportion of well-educated 
American women are privately insured compared with less educated American women. It is 
plausible that women with private health insurance visit a primary care physician more 
regularly and are faster referred to a gynaecologist compared with women who are uninsured 
or covered by governmental insurance programs. Therefore, it would be reasonable to assume 
that the association between level of education and tumour stage at diagnosis of ovarian 
cancer would be more pronounced among the US studies than among the non-US studies. 
However, the results from our additional analysis stratified by study continent were not able 
to support this.  
 
Finally, low SES is known to be associated with less unhealthy lifestyle, including factors 
such as poorer diet, less exercise, more cigarette smoking and higher BMI [46-48]. Both 
cigarette smoking and obesity accelerates carcinogenesis resulting in earlier progression and 
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death, whereas obesity can blur ovarian cancer symptoms and delay diagnosis [49]. However, 
in the present study, BMI and cigarette smoking status had virtually no effect on the estimated 
associations between level of education and tumour stage at diagnosis. Therefore, BMI and 
cigarette smoking do not appear to have substantial influence on tumour stage difference by 
level of education.  
 
A strength of the present study is the large number of ovarian cancer patients obtained by 
pooling data from 18 individual case-control studies. This collection strengthened the 
statistical power of the risk estimates and allowed us to examine associations both overall and 
separately for the various histotypes of ovarian cancer. In addition, the majority of the studies 
were population-based designs with information on education obtained from in-person 
interviews. The participating studies were not selected from among published studies. 
Therefore, our analyses included both positive and negative study-specific results, limiting the 
possibility of publication bias. The present analyses relied on individual data combined into a 
single dataset following careful central data harmonization. We considered differences in 
study design and data collection across studies and adjusted for relevant confounding factors 
across studies. However, we could not adjust for comorbidity, as this information was not 
available in our data. The degree of comorbidity is known to be inversely correlated with SES 
[50] and comorbidity may blur symptoms of cancer and may reduce individual resources 
when it comes to health care seeking. Hence, even though a recent cohort study showed that 
comorbidity only had a small impact on the differences in ovarian cancer stage and survival 
by SES [8], we cannot rule out that our results may have been slightly affected by unmeasured 
confounding from comorbidity. Furthermore, information on tumour stage was abstracted 
from hospital records or cancer registries and the majority of study sites performed pathology 
review in order to confirm histotype classifications. Nevertheless, not all ovarian tumours 
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underwent systematic histopathologic review and therefore some degree of misclassification 
of subtype could have occurred. An additional potential limitation of the present study is that 
we only included one measure of SES - level of education - as only a limited number of 
OCAC studies obtained information on other measures such as income or 
marriage/cohabitation status. Even though a single measure of SES may show an association 
with the health outcome analysed, it may not encompass the entirety of the effect of SES on 
health, and inclusion of multiple measures of SES are always preferable [51]. Hence, by 
including only one measure of SES, we may only partly have explained the true association 
between SES and stage at diagnosis of ovarian cancer. However, level of education is 
considered to be a good and valid measure of SES with regard to health because it influences 
an individuals’ SES throughout life and it is highly associated with both income and 
occupation [6; 52]. Further, knowledge and skills obtained through education may affect 
cognitive functions and thereby strengthen the individuals’ comprehension of health messages 
and communication with health authorities [51]. Finally and perhaps most importantly, for 
most individuals, level of education does not change substantially throughout life compared 
with other measures of SES, including income and occupation, and can therefore be 
considered to be a robust measure of SES [51].  
 
5. Conclusions 
This large pooled analysis showed that lower educational level was associated with advanced 
tumour stage at diagnosis. BMI and cigarette smoking did not explain the association. Hence, 
in order to reduce diagnostic delays, it is important to identify which underlying factors (e.g., 
patient awareness of and response to cancer symptoms, access to healthcare and latency of 
referral to specialist care, lifestyle factors and comorbidities) that contribute to socioeconomic 
differences in tumour stage at diagnosis of ovarian cancer. 
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Table 1 Characteristics of the 18 case-control studies included in the pooled analysis of level of education and stage at diagnosis of ovarian cancer. 
 Region  Study  
Study 
acronym 
 
Study period 
 
Cases 
   N  
 
Women 
diagnosed at 
advanced 
tumour 
stagea 
(%) 
 
Study type 
  
 
 
 
 
 
Age range 
             
Australia Australian Ovarian Cancer Study and  AUS  2002-2006  1,073  950 (88.5)  Population-based  20-80 
 Australian Cancer Study (Ovarian Cancer)            
             
             Europe German Ovarian Cancer Study GER  1993-1996  219  178 (81.3)  Population-based  21-75 
            32-80  The Danish Malignant Ovarian Tumor Study MAL  1994-1999  551  478 (86.8)  Population-based  -  
              Nijmegen Ovarian Cancer Study NTH  1989-2006  254  172 (67.7)  Hospital-based  23-83 
              Polish Ovarian Cancer Case-Control Study POL  2000-2003  183  112 (61.2)  Population-based  27-74 
              Study of Epidemiology and Risk Factors in  SEA  1998-2010  917  522 (56.9)  Population-based  22-74 
 Cancer Heredity            
              UK Ovarian Cancer Population Study  UKO  2006-2010  524  443 (84.5)  Hospital-based  19-89 
             
United States (US) Connecticut Ovarian Cancer Study CON  1998-2003  296  248 (83.8)  Population-based  36-81 
 Diseases of the Ovary and their evaluation DOV  2002-2005  592  504 (85.1)  Population-based  35-74 
              Hawaii Ovarian Cancer Case-Control Study  HAW  1993-2008  681  486 (71.4)  Population-based  24-87 
              Novel Risk Factors and Potential Early Detection  HOP  2003-2009  663  552 (83.3)  Population-based  25-91 
 Markers for Ovarian Cancer            
              Mayo Clinic Ovarian Cancer Case-Control MAY  2000-2009  493  450 (91.3)  Clinic-based  21-91 
 Control Study            
              North Carolina Ovarian Cancer study NCO  1999-2008  849  723 (85.2)  Population-based  22-74 
              New England Case-Control Study  NEC  1992-2003  827  570 (68.9)  Population-based  21-77 
              New Jersey Ovarian Cancer Study NJO  2002-2008  230  184 (80.0)  Population-based  30-81 
              Family Registry for Ovarian Cancer and  STA  1997-2001  488  376 (77.0)  Population-based  21-64 
 Genetic Epidemiology of Ovarian Cancer            
              University California Irvine Ovarian Study UCI  1993-2005  384  310 (80.7)  Population-based  21-86 
 Los Angeles County Case-Control Studies of  USC  1993-2005  1,377  1,073 (77.9)  Population-based  20-84 
 Ovarian Cancer            
                                                                 TOTAL       10,601  8,331 (78,6)    19-91 
a Women diagnosed with regional or distant stage
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Table 2 Characteristics of women diagnosed with epithelial ovarian cancer, according to tumour stage at  
diagnosis. 
  All  Localized stage  Advanced stageb   
     (n = 10,601)    (n = 2,270)    (n = 8,331)   P-value 
         
Age at diagnosis (years)         
  Median  57.0  53.0  58.0  <0.001c 
  Interquartile range  49.0-65.0  45.7-62.0  50.0-66.0   
 
Histology         
  Serous  6,066 (57.2)  501 (22.1)  5,565 (66.8)  <0.001d 
    Serous low-grade  479 (4.5)  98 (4.3)  381 (4.6)   
    Serous high-grade  5,030 (47.4)  339 (14.9)  4,691 (56.3)   
  Endometrioid  1,664 (15.7)  665 (29.3)  999 (12.0)   
  Mucinous  780 (7.4)  480 (21.1)  300 (3.6)   
  Clear cell   875 (8.3)  412 (18.1)  463 (5.6)   
  Othera  1,216 (11.5)  212 (9.3)  1,004 (12.1)   
         
Level of education         
  ≤High school  5,190 (49.0)  1,054 (46.4)  4,136 (49.6)  0.008d 
  >High school  5,411 (51.0)  1,216 (53.6)  4,195 (50.4)   
         
BMI         
  Median  24.0  23.6  24.1  <0.001c 
  Interquartile range  21.4-28.2  20.9-28.0  21.5-28.2   
 
Smoking status         0.02d 
  Never  5,770 (54.4)  1,227 (54.1)  4,543 (54.5)   
  Former          3,391 (32.0)  694 (30.6)  2,697 (32.4)   
  Current   1,440 (13.6)  349 (15.4)  1,091 (13.1)   
         
Race/ethnicity        <0.001d 
  Non-Hispanic White  9,129 (86.1)  1,878 (82.7)  7,251 (87.0)   
  Hispanic White  306 (2.9)  62 (2.7)  244 (2.9)   
  Black  265 (2.5)  53 (2.3)  212 (2.5)   
  Asian  565 (5.3)  190 (8.4)  375 (4.5)   
  Other   331 (3.1)   87 (3.8)   244 (2.9)    
a Includes mixed cell, undifferentiated and tumours of unknown histology 
b Includes regional or distant stage 
c The P-value was calculated using the Wilcoxon rank sum statistical test as the data were not normally distributed 
d The P-value was calculated using the Pearson’s chi square statistical test at the data were normally distributed 
Numbers may not sum up to total because of missing data  
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Table 3 Adjusted pooled odds ratios (pORs) and 95% confidence intervals (95% CI) for the association  
between level of education and advanced stage at diagnosis of ovarian cancer, overall and by histotype. 
  Model 1a  Model 2b 
  Cases (n = 10,601)  pOR (95% CI)  Cases (n = 10,457)  pOR (95% CI) 
Overall  
 
       
  >high school  5,411  1.00  5,362  1.00 
  ≤high school  5,190  1.15 (1.03-1.28)  5,095  1.18 (1.05-1.32) 
         
Serous          
  >high school  3,003  1.00  2,973  1.00 
  ≤high school  3,063  1.08 (0.87-1.34)  3,009  1.13 (0.90-1.41) 
         
Serous low-grade         
  >high school  143  1.00  142  1.00 
  ≤high school  228  1.10 (0.51-2.35)  228  1.23 (0.49-3.12) 
         
Serous high-grade         
  >high school  2,568  1.00  2,541  1.00 
  ≤high school  2,462  1.02 (0.78-1.32)  2,413  1.09 (0.83-1.43) 
         
Endometrioid         
  >high school  908  1.00  901  1.00 
  ≤high school  756  1.10 (0.86-1.42)  749  1.17 (0.90-1.53) 
         
Mucinous         
  >high school  349  1.00  349  1.00 
  ≤high school  271  0.97 (0.63-1.48)                 266  1.09 (0.68-1.76) 
         
Clear cell         
  >high school  436  1.00  431  1.00 
  ≤high school  390  1.19 (0.84-1.71)  376  1.21 (0.83-1.77) 
aAdjusted for age (continuous variable) and race/ethnicity (Non-Hispanic White, Hispanic White, Black, Asian and other). 
bAdjusted for the two factors in Model 1 plus adjustment for BMI (continuous variable) and cigarette smoking status (never, 
former or current). 
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Figure Legends 
Fig. 1. Risk of advanced tumour stage at diagnosis of ovarian cancer associated with level of education by 
study site and overall. Study-specific odds ratios (ORs) and 95% confidence intervals (CIs) were estimated 
using logistic regression models adjusted for age and race/ethnicity. The pooled odds ratio (pOR) with 
corresponding 95% CI was estimated using a random effects model. Level of education was parameterized 
as women who completed high school or less versus women who completed more than high school 
 
